


NANETS Multidisciplinary NET Medical
SYMPOSIUM

Abstract Poster Quick Guide



POSTER HALL MAP



NANETS Multidisciplinary NET Medical
SYMPOSIUM

October 27-29, 2022

JW Marriott | Washington, DC

Category 1: Basic Science

Poster #	Title	Presenter Name	Institution	Abstract ID
B-1	Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors	Shreya Rajhans, BS	National Cancer Institute, NIH	21437
B-2	Multiple Layers of Epigenetic Regulation Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors	James Madigan, PhD	National Cancer Institute, NIH	21438
B-3	Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors	Eleonora Pelle, MD	H. Lee Moffitt Cancer Center and Research Institute	21446
B-4	Simultaneous Inhibition of DNA Methylation and Histone Deacetylation for Enhanced SSTR2 Expression in Vitro	Jason Whitt, PhD	University of Alabama at Birmingham	21460
B-5	Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-Tumor Response in a Syngeneic Tumor Model	Aman Chauhan, MD	University of Kentucky	21463
B-6	Detecting Cell Surface Expression of Calreticulin in Pancreatic Neuroendocrine Tumors Using a Novel [68Ga]-Radiolabeled Peptide	Rachael Guenter, PhD	University of Alabama at Birmingham	21466
B-7	All-Trans Retinoic Acid Radiosensitizes Neuroendocrine Tumor Cells via Peptidyl-prolyl Cis-Trans Isomerase 1 Inhibition	Jason Schwarz, MD	University of Chicago	21472
B-8	CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors	Courtney Kaemmer, BS	University of Iowa	21475
B-9	Deletion of Notch1 Signaling in Pancreatic Neuroendocrine Tumors Reduces Metastatic Properties	Weisheng Chen, ME	University of Alabama at Birmingham	21479
B-10	Inhibition of Estrogen Receptor Alpha Radiosensitizes Neuroendocrine Tumors	Jason Schwarz, MD	University of Chicago	21557
B-11	Patient-Derived Organoids and Their Potential for Precision Medicine in Neuroendocrine Tumors	Briana Cortez, BS	Developmental Therapeutics Branch, National Cancer Institute, NIH	21564

Category 1: Basic Science

Poster #	Title	Presenter Name	Institution	Abstract ID
B-12	Transcriptomic Influences of Racial Disparities in Black Patients with Pancreatic Neuroendocrine Tumors.	Brendon Herring, MS	University of Alabama at Birmingham School of Medicine	21456
B-13	Optical Genome Mapping: a Novel Approach to Identifying Structural Variants in Metastatic Neuroendocrine Tumors	Daniel DePietro, MD	Hospital of the University of Pennsylvania	21477
B-14	Pancreatic Mixed Acinar-Neuroendocrine Carcinoma: a Single Institutional Genomic Characterization Report	Manik Amin, MD	Dartmouth Hitchcock Medical Center	21566
B-15	Targeting the TCA Cycle with Histone Deacetylase and Nicotinamide Phosphoribosyltransferase Inhibitors Uncovers a Critical Role for YAP1 in Neuroendocrine Cells	Maryam Safari, MD	Columbia University Medical Center	21574
B-16	[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors – Comparison to [177Lu] DOTATATE in a Preclinical Model	Michael Schultz, PhD	University of Iowa	21938

Category 2: Chemo/SSA/Biologics (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-1	Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm	Simron Singh, MD, MPH	University of Toronto, Odette Cancer Center, Sunnybrook Health Sciences Center	21377
C-2	Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms	Lindsay Hunter, MD	Huntsman Cancer Institute	21389
C-3	Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)	Callisia Clarke, MD, MS, FACS, FSSO	Medical College of Wisconsin	21424
C-4	Cisplatin vs Carboplatin in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas (PD NEC)	Nicole McLaughlin, MD	Mayo Clinic	21435

Category 2: Chemo/SSA/Biologics (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-5	c-MET Expression in MEN1-Associated Neuroendocrine Tumors	Smita Jha, MD	National Institutes of Health	21443
C-6	An Open-Label, Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors	Jennifer Eads, MD	Penn Medicine	21448
C-7	Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate	Taymeyah Al-Toubah, MPH	H. Lee Moffitt Cancer Center and Research Institute	21451
C-8	Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors	Taymeyah Al-Toubah, MPH	H. Lee Moffitt Cancer Center and Research Institute	21453
C-9	Correlation of MEN1 and DAXX Mutational Status with Response to Capecitabine and Temozolomide (CAPTEM) in Pancreatic Neuroendocrine Tumors	Andrew Hendifar, MD	Cedars-Sinai Medical Center	21454
C-10	ACTH-Secreting Pancreatic Neuroendocrine Neoplasms: A Case-Series	Eleonora Pelle, MD	H. Lee Moffitt Cancer Center and Research Institute	21455
C-11	Results from the Phase 1, Randomized, Open-Label, Cross-Over Study to Evaluate Pharmacokinetics of Three Escalating Doses of Oral Octreotide Capsules	Shir Fuchs Orenbach, MD, MSc	Amryt Pharma	21458
C-12	Financial Toxicity and Supportive Care in Neuroendocrine Tumor: A Biobank Study	Arya Mariam Roy, MD	Roswell Park Comprehensive Cancer Center	21469
C-13	Serum Serotonin Compared to Plasma 5-HIAA and Chromogranin A as Biomarkers of Response to Hepatic Artery Bland Embolization	Lowell B. Anthony, MD, FACP	University of Kentucky	21520

Category 3: Nuclear Medicine/Interventional Radiology/Imaging (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-14	Cardiac Neuroendocrine Tumor Metastases on 68Ga-DOTATATE PET/CT	Hwan Lee, MD	University of Pennsylvania	21260

Category 3: Nuclear Medicine/Interventional Radiology/Imaging (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-15	Effectiveness and Safety of Re-treatment with ¹⁷⁷ Lu-DOTATATE in Patients with Progressive NETs in the US: a Retrospective Real-World Study	Ebrahim Delpassand, MD	Excel Diagnostics & Nuclear Oncology Center	21354
C-16	Clinical Utility of Somatostatin Receptor Positron Emission Tomography Imaging Biomarkers for Characterization of Meningioma Among Incidental Central Nervous System Lesions	Muskan Agarwal, MD	Mayo Clinic Arizona	21355
C-17	Integration of Radioembolization with CapTem for Liver-Dominant G2 NETs: Long-Term Outcomes	Michael Soulen, MD, FSIR, FCIRSE	Abramson Cancer Center University of Pennsylvania	21371
C-18	Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?	Michael Soulen, MD, FSIR, FCIRSE	Abramson Cancer Center University of Pennsylvania	21372
C-19	Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): a Case Series	Igryl Cordero-Hernandez, MD	UT MD Anderson Cancer Center	21416
C-20	Quality of Life Assessments for Advanced Pheochromocytoma and Paraganglioma Patients that Received High-Specific-Activity I-131 MIBG: Results from a Pivotal Phase 2 Clinical Trial	Camilo Jimenez, PhD	MD Anderson Cancer Center	21417
C-21	Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET	Tucker Coston, MD	Mayo Clinic	21449
C-22	The Role of ⁶⁸ Ga-DOTATATE PET/CT in the Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors	Orjola Prela, MD	University of Rochester	21450
C-23	Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: an Analysis of Dotatate PET Scans	Taymeyah Al-Toubah, MPH	H. Lee Moffitt Cancer Center and Research Institute	21452
C-24	MIBG and DOTATATE Therapy for Pheochromocytoma and Paraganglioma: a Single Institution Experience	Erik S. Mitra, MD, PhD	Oregon Health & Science University	21473

Category 3: Nuclear Medicine/Interventional Radiology/Imaging (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-25	Evaluation of 68Ga-DOTATATE PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)	Heying Duan, MD	Stanford University	21480
C-26	Pre-therapy Functional Imaging with MIBG and DOTATATE to Guide Radiopharmaceutical Therapy for Pheochromocytoma and Paraganglioma: a Single Institution Experience	Nadine Mallak, MD	Oregon Health & Science University	21573
C-27	Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CT, and MRI Spine in the Detection of Spinal Bone Metastases in Metastatic Pheochromocytoma/Paraganglioma	Abhishek Jha, MD	National Institutes of Health	21579
C-28	Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-Related-Pheochromocytoma	Abhishek Jha, MD	National Institutes of Health	21580
C-29	Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-Related Pheochromocytoma	Abhishek Jha, MD	National Institutes of Health	21581

Category 4: Surgery/Applied Pathology (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-30	Liver-Directed Therapy of Neuroendocrine Liver Metastases	Julie Hallet, MD, MSc, FRCSC, FSSO	University of Toronto	21263
C-31	Goblet Cell Adenocarcinoma (GCA) of the Appendix: Interrogating Proteomics to Identify Potential Actionable Targets	Satya Das, MD, MSCI	Vanderbilt University Medical Center	21374
C-32	Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: a Systematic Review and Meta-Analysis	James R. Howe, MD	University of Iowa	21402
C-33	High-Grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathological and Molecular Characteristics	Mehran Taherian, MD	MD Anderson Cancer Center	21411
C-34	Grade Creep and the Importance of Tissue Sampling: Changes in Ki-67 and Grade in Serial Neuroendocrine Tumor Samples	Suzie Byun, SB	University of Pennsylvania	21415

Category 4: Surgery/Applied Pathology (Clinical)

Poster #	Title	Presenter Name	Institution	Abstract ID
C-35	Liver Directed Therapy is Associated with Improved Survival in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms with Concurrent Bone Metastasis	Kristen Limbach, MD	City of Hope National Medical Center - Duarte, CA	21421
C-36	Impact of Primary Tumor Resection in the Management of Metastatic Well-Differentiated Neuroendocrine Tumors of the Small Bowel and Pancreas	Ashley Russo, MD	Cedars-Sinai Medical Center	21432
C-37	Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?	Luis Borbon, MD	University of Iowa Hospitals and Clinics	21440
C-38	Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - a Contemporary Analysis	Seth Concors, MD	MD Anderson Cancer Center	21444
C-39	Have We Accounted for Asians? A Critical Analysis of Racial Cancer Disparity Amongst Asian Pancreatic Neuroendocrine Tumor Patients	Katherine McElroy, MD	The University of Alabama at Birmingham	21447
C-40	TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors	Nancy Joseph, MD, PhD	University California San Francisco	21470
C-41	SSTR-2 Expression in Solid Tumors: An Immunohistochemistry Analysis	Aman Chauhan, MD	University of Kentucky	21481
C-42	Small Intestinal NET Recurrence – When Why and How?	Priya Pai, MBBS	Mayo Clinic	21565
C-43	Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis	Michael Lui, MD	MD Anderson Cancer Center	21577

Category 5: Population Science

Poster #	Title	Presenter Name	Institution	Abstract ID
P-1	Cervical Neuroendocrine Carcinomas: a Population-Based Analysis of Clinicopathologic Characteristics and Survival Outcomes in Comparison with Conventional Cervical Malignancies	Leonidas Diamantopoulos, MD	University of Pittsburgh Medical Center	21336

Category 5: Population Science

Poster #	Title	Presenter Name	Institution	Abstract ID
P-2	Factors Impacting Survival Outcomes of Islet Cell Carcinoma	Tiffany Chu, BS, BA	Creighton University School of Medicine	21380
P-3	Socioeconomic Factors, Treatment Modality, and Survival in Islet Cell Carcinoma: a National Cancer Database Analysis	Robert Hu, BA	Creighton University School of Medicine	21386
P-4	Carcinoid Heart Disease in Patients Diagnosed with Small Bowel and Lung Neuroendocrine Tumors	Julie Hallet, MD, MSc, FRCSC, FSSO	University of Toronto	21400
P-5	Comparison of Demographics and Overall Survival (OS) Among Patients with Young-Onset(YO) and Late-Onset(LO) GI Neuroendocrine Tumors/Carcinomas (NETs/NECs) in the United States	Bahar Laderian, MD	Cleveland Clinic Foundation	21409
P-6	Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	Tariqa Ackbarali, PhD	PlatformQ Health	21418
P-7	Feasibility of e-NET: a Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors	Claire Mulvey, MD	University of California San Francisco	21430
P-8	Multivisceral Surgical Resection of Locally Advanced Pancreatic Neuroendocrine Tumor is Associated with a Survival Benefit	Matthew Hernandez, MD	City of Hope National Medical Center	21439
P-9	Lifestyle and Neuroendocrine Tumor (NET) Development within the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort	Marit Bogaards, BSc	University Medical Center Utrecht (UMCU)	21459
P-10	Environmental Pollution and GEP-NENS – Is There an Association?	Philip Ituarte, PhD	City of Hope National Medical Center	21468

Category 6: Other

Poster #	Title	Presenter Name	Institution	Abstract ID
O-1	Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis	Satya Das, MD, MSCI	Vanderbilt University Medical Center	21373

Category 6: Other

Poster #	Title	Presenter Name	Institution	Abstract ID
O-2	The Association Between Patient-Reported Symptom Burden and Urgent Healthcare Use in Patients Diagnosed with Neuroendocrine Tumors	Julie Hallet, MD, MSc, FRCSC, FSSO	University of Toronto	21401
O-3	Germline Pathogenic Variants in Patients with High-Grade (G3) Metastatic Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)	Farhana Moon, MPH	University of California San Francisco	21410
O-4	Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response	Orla Maguire, PhD	Roswell Park Comprehensive Cancer Center	21431
O-5	Implementation of a Patient Advisor Program for Neuroendocrine Tumor Patients: Acceptability, Benefits and Potential Challenges	Florence Bénard, MD	Centre Hospitalier de l'Université de Montréal (CHUM)	21433
O-6	Frequency of Pulmonary Carcinoid Tumor Research Presented at Major International Neuroendocrine and Lung Cancer Scientific Meetings	Robert Ramirez, DO	Vanderbilt University Medical Center	21462
O-7	Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumor Patients	Lindsay Hunter, MD	University of Utah	21465
O-8	Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)	Farhana Moon, MPH	University of California, San Francisco	21471
O-9	Leveraging Transcriptomics to Grade Pancreatic Neuroendocrine Neoplasms (NENs) and Assess Molecular Alterations Associated with Somatostatin Receptor (SSTR) Subtype Expression	Heloisa Soares, MD, PhD	University of Utah	21474
O-10	Germline Cancer Testing in Unselected Patients with Neuroendocrine Neoplasms: a Multi-center Prospective Study	Mohamad Sonbol, MD	Mayo Clinic	21476
O-11	Pheo Para Alliance Patient Centered Research on Challenges for Those with Pheochromocytoma and Paraganglioma	Lauren Fishbein, MD, PhD	University of Colorado	21562
O-12	An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or is it Redundant?	Nikolaos Trikalinos, MD	Washington University in St Louis	21582

Category 7: Trials in Progress

Poster #	Title	Presenter Name	Institution	Abstract ID
T-1	Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with A Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma	Shannon Stockton, MD	Vanderbilt University Medical Center	21375
T-2	COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-Edotreotide with Best Standard of Care	Thorvardur Halfdanarson, MD	Mayo Clinic Rochester	21387
T-3	Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome	Keith Usiskin, MD	Crinetics Pharmaceuticals	21388
T-4	Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon- β and NIS (VSV-IFN β -NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma	Patrick McGarrah, MD	Mayo Clinic	21395
T-5	A Phase 2 Open-Label Study of Belzutifan (a HIF-2 α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors	Camilo Jimenez, MD	The University of Texas MD Anderson Cancer Center	21413
T-6	ACTION-1: A Randomized Phase Ib/3 Trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA	Thomas Hope, MD	University of California San Francisco	21414
T-7	Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET	Simron Singh, MD, MPH, FRCPC	University of Toronto, Odette Cancer Center, Sunnybrook Health Sciences Center	21419
T-8	Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)	Aman Chauhan, MD	University of Kentucky Markey Cancer Center	21423
T-9	PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy Versus PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors	Ameya Puranik, MD	Tata Memorial Center	21441

Category 7: Trials in Progress

Poster #	Title	Presenter Name	Institution	Abstract ID
T-10	Pilot Study of TQ Formula in Combination with Nivolumab and Ipilimumab in Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECAs)	Amr Mohamed, MD	UH Seidman Cancer Center, Case Western Reserve University	21559

